PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
PRTC Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
PureTech Health plcNASDAQ: PRTC
Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025
Depreciation & amortization declines year over year
Q4 FY2025 depreciation & amortization of $1.65M fell 6.1% year over year. Over 3 fiscal years it compounded at -27.8% a year.
Context
- Depreciation & amortization amounted to 71.9% of revenue in FY2025, down 2.1 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.35M USD
- Year-over-year change
- -6.2%
- 4-year CAGR
- -17.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.35M | -6.2% |
| FY2024 | 2024-12-31 | 3.57M | -27.6% |
| FY2023 | 2023-12-31 | 4.93M | -44.5% |
| FY2022 | 2022-12-31 | 8.89M | +22.9% |
| FY2021 | 2021-12-31 | 7.24M | — |
Depreciation & Amortization vs competitors
How PRTC compares with its peers on the latest reported figures
- PRTC's FY2025 depreciation & amortization of $3.35M is the 4th highest of the 11 companies compared; the peer median is $2.14M.
- Its year-over-year change of -6.2% is the 7th highest of 11, against a peer median of +0.5%.
- Depreciation & amortization amounts to 71.9% of revenue for PRTC, versus a peer median of 14.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13M | +24.1% | +9.8% | 14.0% | |
| LTM Mar 2026 | $10.18M | +1.0% | +20.7% | — | |
| LTM Mar 2026 | $4.76M | +6.9% | +19.9% | 257.1% | |
| FY2025 | $3.35M | -6.2% | -27.8% | 71.9% | |
| LTM Mar 2026 | $3.18M | +0.0% | -1.1% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.65M | -20.7% | +140.9% | 35.9% |
| LTM Mar 2026 | $1.62M | -35.9% | -12.1% | — | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $723K | +20.9% | -1.3% | 4.9% | |
| LTM Mar 2026 | $475K | +28.7% | +0.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding PRTC) | $2.14M | +0.5% | -0.4% | 14.0% | |
Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.98M | 2.09M | 3.33M | 4.83M | 4.66M |
| Cost of Revenue | 110.47M | 152.43M | 4.93M | 3.57M | 3.36M |
| Gross Profit | (100.49M) | (136.82M) | (1.6M) | 1.26M | 4.66M |
| Gross Margin | -1007.0% | -6546.2% | -48.1% | 26.0% | 100.0% |
| Research & Development | 81.52M | 116.11M | 96.24M | 54.28M | 45.74M |
| Selling, General & Admin | 30.76M | 35.67M | 48.36M | 27.49M | 20.65M |
| Operating Expenses | 160.26M | 60.99M | 54.55M | 140.41M | 103.18M |
| Depreciation & Amortization | 7.24M | 8.89M | 4.93M | 3.57M | 3.35M |
| EBITDA | 26.7M | (188.91M) | (11.63M) | 37.38M | (61.8M) |
| EBITDA Margin | 267.6% | -9038.9% | -349.2% | 774.3% | -1326.5% |
| Operating Income | (150.28M) | (197.81M) | (146.2M) | (136.1M) | (98.53M) |
| Operating Margin | -1506.0% | -9464.4% | -4390.4% | -2818.9% | -2114.7% |
| Interest Income | 214K | 5.8M | 16.01M | 22.67M | 13.05M |
| Interest Expense | 4.71M | 3.95M | 13.49M | 10.04M | 45.78M |
| Other Income / Expenses | 91.33M | 105.02M | 110.1M | 159.87M | (12.4M) |
| Income Before Tax | (58.95M) | (92.78M) | (36.1M) | 23.77M | (110.93M) |
| Pre-Tax Margin | -590.8% | -4439.4% | -1084.2% | 492.4% | -2380.9% |
| Income Tax Expense | 3.76M | (55.72M) | 30.53M | (4.01M) | (842K) |
| Net Income | (60.56M) | (50.36M) | (65.7M) | 53.51M | (109.74M) |
| Net Margin | -606.9% | -2409.3% | -1972.9% | 1108.3% | -2355.4% |
| EPS (Basic) | (2.10) | (1.80) | (2.40) | 2.00 | (46.00) |
| EPS (Diluted) | (2.10) | (1.80) | (2.40) | 2.00 | (46.00) |
| Weighted Avg Shares | 28.66M | 27.97M | 27.63M | 26.97M | 2.41M |
| Weighted Avg Shares (Diluted) | 28.66M | 28.48M | 27.63M | 26.97M | 2.41M |
PureTech Health plc
NASDAQ:PRTC
Intrinsic Alpha fair value
Locked
Current Price
$17.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.